Sequentially obtained serum samples from 30 patients with connective tissue disease positive for antibody to ribonucleoprotein (RNP) were examined to determine the specificities of IgG and IgM antibodies to snRNP during the disease course using immunoblotting of nuclear extracts. The antibody patterns were correlated with disease activity. The patterns of antibody to snRNP of individual patients were mainly stable during the study but changes in levels of antibody to snRNP were seen corresponding to changes in clinical activity. These results indicate that increased reactivity of serum IgM antibodies against the B/B' proteins seems to precede a clinicaily evident exacerbation of disease whereas IgG antibody reactivity to the 70 K protein peaks at the time of a disease flare.
Autoantibodies reacting with different nuclear and cytoplasmic constituents are characteristically found in serum samples from patients with connective tissue diseases. The presence of some of these autoantibodies is associated with particular clinical manifestations.' High serum titres of IgG antibodies reacting with a ribonucleoprotein (RNP) antigen was thus included as one of the defining criteria of mixed conective tissue disease in a group of patients with connective tissue disease sharing clinical features with systemic lupus erythematosus, progressive systemic sclerosis, and polymyositis.2 Autoantibodies to RNP are also found in serum samples from patients with SLE but usually in lower titres and often associated with antibodies of another specificity designated antibodies to Sm.3 Antibodies to RNP and Sm react with different protein components of the U snRNPs, a group of small nuclear RNA protein complexes involved in the splicing of hnRNA.' Antibodies to RNP recognise the 70K, A, and C proteins unique to the Ul snRNP RNA-protein complex.57 The major RNP antigen is the 70K protein."' Antibodies to Sm recognise epitopes present on the B/B' and D proteins, which are common to all the UsnRNPs."
With at least five different RNP and Sm antigenic snRNP proteins identified, investigators have re-examined the initially observed associations between the presence of antibodies to RNP and Sm in serum samples and certain clinical findings.9 [12] [13] [14] [15] Statistically significant correlations between reactivity against specific snRNP proteins and the presence of certain clinical symptoms and signs have been reported.8 10 14 [16] [17] [18] [19] In one longitudinal study decreasing titres of antibodies to RNP were found in patients with connective tissue disease in prolonged clinical remission following intensive treatment with corticosteroids and cytotoxic drugs, indicating an association between changes in clinical manifestations and changes in antibody titre.9 In another longitudinal study of patients with connective tissue disease with mild disease and few occasions of exacerbation of disease a clearcut correlation between changes in antibody titre and clinical activity was not found.'7 This indicates that apart from methodological differences in the detection of autoantibodies patient selection is crucial and greatly affects the outcome of different studies.
The aim of this investigation was to study the specificities of antibodies to snRNP in sequentially obtained serum samples during the disease course of patients positive for antibody to RNP. The patients were initially selected only on the basis of being positive for antibody to RNP and were then followed up regularly. A further purpose of this longitudinal study was to analyse whether changes in antibodies to snRNP of both the IgG and IgM isotypes were correlated to changes in disease activity. 
Patients and methods

PATIENTS
Prim. SS 54 Minimal serological changes were observed for seven patients. Six of these had a clinically low C Z 3 4 5 6 7 8 9 10 More pronounced changes in IgG reactivity against snRNP were noted in serum samples from patients receiving constant or intermittent drug treatment. In these patients, corticosteroids and immunosuppressive drugs were mainly used in the treatment of recurrent pulmonary changes or relapsing polymyositis. The antibody changes seen in treated patients were manifested as an increased or decreased IgG reactivity primarily against the 70K protein but could also include changing IgG reactivity against the A, C, and B/B' proteins. In a few patients recruitment of new specificities was observed. In neither instance was it possible to detect a common order of appearance or disappearance of specificities.
It appeared that an increased reactivity against snRNP correlated with an aggravation of the clinical status of the patient. In patients with mild aggravation of clinical symptoms or symptoms suppressed by drug treatment an increased reactivity against snRNP could still be observed. In no patient was a major change in clinical status observed without concomitant changes in antibody reactivity.
IgM antibodies reacting with snRNP proteins were present in 26 of the 30 series of serum samples tested. In contrast with the IgG results, IgM antibodies to the 70K protein were only detected in nine patients. The most commonly observed specificity was antibodies to B/B' (table). IgM antibodies against the A and C proteins were also often represented, however. Interestingly, these specificities were present in some serum samples for seven years without switching to the IgG isotype. In other serum samples a coexistence between IgG and IgM antibodies to snRNP directed towards the same polypeptides was observed over a period of several years.
As for the IgG antibodies, all IgM antibodies to snRNP showed fluctuations in levels of staining intensity. These variations were more pronounced in patients with clinically active disease. In addition, in most patients the changes seemed to be correlated with major disease activity by preceding exacerbation of disease. In one patient (No 11, fig 3C) drug treatment (prednisolone) was initiated when myositis was observed and subsequently withdrawn after a clinically calm period. At this time the IgM reactivity against B/B' was increasing but the IgG reactivity to the 70K protein was still unchanged. At the next observation point an increase in the level of the IgG reactivity against the 70K protein was detected and eventually a flare of disease developed. The patient was treated with steroids again and improved clinically. The reactivities of IgM against B/B' and IgG against 70K had then already peaked and were decreasing. From our observations it seems that the variation in the levels of antibody to snRNP rather than the level per se is coupled to disease activity. Especially noteworthy is the observation that changes in the level of the IgM antibodies against B/B' seem to precede the clinically observed flares, even though they might also reflect an increase in total IgM levels.
In conclusion, our observations suggest that for certain patients positive for autoantibody to RNP with an active connective tissue disease, reactivity against the 70K protein by IgG antibodies peaks at the time of exacerbation of disease. In addition, increased reactivity by IgM antibodies against the B/B' proteins seems to precede the increase in reactivity to the 70K protein as well as the clinically evident exacerbation in the individual patient. A larger number of patients should be analysed prospectively to establish these observations.
